(Q37755129)

22 August 2017

title

Aspects of beta-amyloid as a biomarker for Alzheimer's disease (English)

1 reference

22 August 2017

0 references

0 references

5

Henrik Zetterberg

1 reference

22 August 2017

4

Kaj Blennow

1 reference

22 August 2017

2

Erik Portelius

1 reference

22 August 2017

1

Ulf Andreasson

1 reference

22 August 2017

Malin E Andersson

3

1 reference

22 August 2017

publication date

1 June 2007

1 reference

22 August 2017

published in

Biomarkers in Medicine

1 reference

22 August 2017

volume

1

1 reference

22 August 2017

issue

1

1 reference

22 August 2017

page(s)

59-78

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

22 August 2017

1 reference

The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Amyloid plaque core protein in Alzheimer disease and Down syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Neuritic plaques and cerebrovascular amyloid in Alzheimer disease are antigenically related

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Amyloid beta-peptide is produced by cultured cells during normal metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Production of the Alzheimer amyloid beta protein by normal proteolytic processing

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

The presenilin hypothesis of Alzheimer's disease: evidence for a loss-of-function pathogenic mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Alzheimer's disease: a dysfunction of the amyloid precursor protein(1).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Axonal transport and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta-analysis of individual patient data from randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Take five--BACE and the gamma-secretase quartet conduct Alzheimer's amyloid beta-peptide generation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

The proteolytic processing of the amyloid precursor protein gene family members APLP-1 and APLP-2 involves alpha-, beta-, gamma-, and epsilon-like cleavages: modulation of APLP-1 processing by n-glycosylation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

The amyloid-beta precursor protein: integrating structure with biological function

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

APP processing and the APP-KPI domain involvement in the amyloid cascade.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Novel precursor of Alzheimer's disease amyloid protein shows protease inhibitory activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

A new A4 amyloid mRNA contains a domain homologous to serine proteinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Protease inhibitor domain encoded by an amyloid protein precursor mRNA associated with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Expression of beta amyloid protein precursor mRNAs: recognition of a novel alternatively spliced form and quantitation in Alzheimer's disease using PCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

The predominant form of the amyloid beta-protein precursor in human brain is protease nexin 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Relative increase in Alzheimer's disease of soluble forms of cerebral Abeta amyloid protein precursor containing the Kunitz protease inhibitory domain.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

The functions of mammalian amyloid precursor protein and related amyloid precursor-like proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

A transcriptionally [correction of transcriptively] active complex of APP with Fe65 and histone acetyltransferase Tip60

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

The intracellular domain of the beta-amyloid precursor protein is stabilized by Fe65 and translocates to the nucleus in a notch-like manner

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Amyloid precursor protein expression in the rat hippocampal dentate gyrus modulates during memory consolidation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Structure and function of amyloid in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Physicochemical characteristics of soluble oligomeric Abeta and their pathologic role in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Different conformations of amyloid beta induce neurotoxicity by distinct mechanisms in human cortical neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Characterization of beta-amyloid peptide from human cerebrospinal fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

The role of cell-derived oligomers of Abeta in Alzheimer's disease and avenues for therapeutic intervention.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

A specific amyloid-beta protein assembly in the brain impairs memory

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Aph-1, Pen-2, and Nicastrin with Presenilin generate an active gamma-Secretase complex

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Identification of a Novel Aspartic Protease (Asp 2) as β-Secretase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Purification and cloning of amyloid precursor protein beta-secretase from human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Expression analysis of BACE2 in brain and peripheral tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

ASP1 (BACE2) cleaves the amyloid precursor protein at the beta-secretase site

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

The gene encoding DRAP (BACE2), a glycosylated transmembrane protein of the aspartic protease family, maps to the down critical region

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

BACE2, a beta -secretase homolog, cleaves at the beta site and within the amyloid-beta region of the amyloid-beta precursor protein

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Identification of a beta-secretase activity, which truncates amyloid beta-peptide after its presenilin-dependent generation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Beta-secretase cleavage at amino acid residue 34 in the amyloid beta peptide is dependent upon gamma-secretase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Antagonistic effects of beta-site amyloid precursor protein-cleaving enzymes 1 and 2 on beta-amyloid peptide production in cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Sorting through the cell biology of Alzheimer's disease: intracellular pathways to pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Inhibition of dynamin-dependent endocytosis increases shedding of the amyloid precursor protein ectodomain and reduces generation of amyloid beta protein

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Rab5-stimulated up-regulation of the endocytic pathway increases intracellular beta-cleaved amyloid precursor protein carboxyl-terminal fragment levels and Abeta production

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Inhibition of cathepsin B reduces beta-amyloid production in regulated secretory vesicles of neuronal chromaffin cells: evidence for cathepsin B as a candidate beta-secretase of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Cysteine proteases are the major β‐secretase in the regulated secretory pathway that provides most of the β‐amyloid in Alzheimer's disease: Role of BACE 1 in the constitutive secretory pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Beta-amyloid peptide in regulated secretory vesicles of chromaffin cells: evidence for multiple cysteine proteolytic activities in distinct pathways for beta-secretase activity in chromaffin vesicles

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Activity-dependent isolation of the presenilin- gamma -secretase complex reveals nicastrin and a gamma substrate

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Presenilin 1 controls gamma-secretase processing of amyloid precursor protein in pre-golgi compartments of hippocampal neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

The discrepancy between presenilin subcellular localization and gamma-secretase processing of amyloid precursor protein

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Presenilin-1 affects trafficking and processing of betaAPP and is targeted in a complex with nicastrin to the plasma membrane

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Nicastrin, presenilin, APH-1, and PEN-2 form active gamma-secretase complexes in mitochondria

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Transition-state analogue inhibitors of gamma-secretase bind directly to presenilin-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Generation of C-terminally truncated amyloid-beta peptides is dependent on gamma-secretase activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Reconstitution of gamma-secretase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Nicastrin binds to membrane-tethered Notch

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and betaAPP processing

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

The role of presenilin cofactors in the gamma-secretase complex

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

PEN-2 and APH-1 coordinately regulate proteolytic processing of presenilin 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Zebrafish lacking Alzheimer presenilin enhancer 2 (Pen-2) demonstrate excessive p53-dependent apoptosis and neuronal loss

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

The cytosolic loop of the gamma-secretase component presenilin enhancer 2 protects zebrafish embryos from apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Cleavage of amyloid beta peptide during constitutive processing of its precursor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

The "nonamyloidogenic" p3 fragment (amyloid beta17-42) is a major constituent of Down's syndrome cerebellar preamyloid

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Abeta 17-42 in Alzheimer's disease activates JNK and caspase-8 leading to neuronal apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Soluble amyloid precursor protein alpha reduces neuronal injury and improves functional outcome following diffuse traumatic brain injury in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

ADAM10 activation is required for green tea (-)-epigallocatechin-3-gallate-induced alpha-secretase cleavage of amyloid precursor protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Membrane-anchored metalloprotease MDC9 has an alpha-secretase activity responsible for processing the amyloid precursor protein

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Evidence for an interaction of the metalloprotease‒disintegrin tumour necrosis factor α convertase (TACE) with mitotic arrest deficient 2 (MAD2), and of the metalloprotease‒disintegrin MDC9 with a novel MAD2-related protein, MAD2β

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha -secretase ADAM 10.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Constitutive shedding of the amyloid precursor protein ectodomain is up-regulated by tumour necrosis factor-alpha converting enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

A novel epsilon-cleavage within the transmembrane domain of the Alzheimer amyloid precursor protein demonstrates homology with Notch processing

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Presenilin-dependent gamma-secretase processing of beta-amyloid precursor protein at a site corresponding to the S3 cleavage of Notch

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Insulin degradation: progress and potential

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Alzheimer's beta-amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Degradation of Alzheimer's beta-amyloid protein by human and rat brain peptidases: involvement of insulin-degrading enzyme.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Amyloid-beta peptide levels in brain are inversely correlated with insulysin activity levels in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Insulin-degrading enzyme in the Alzheimer's disease brain: prominent localization in neurons and senile plaques

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Degradation of soluble amyloid beta-peptides 1-40, 1-42, and the Dutch variant 1-40Q by insulin degrading enzyme from Alzheimer disease and control brains.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-epsilon4 allele

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

The neprilysin (NEP) family of zinc metalloendopeptidases: genomics and function

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Neprilysin degrades both amyloid beta peptides 1-40 and 1-42 most rapidly and efficiently among thiorphan- and phosphoramidon-sensitive endopeptidases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Human neprilysin is capable of degrading amyloid beta peptide not only in the monomeric form but also the pathological oligomeric form

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Metabolic regulation of brain Abeta by neprilysin.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Decreased expression and activity of neprilysin in Alzheimer disease are associated with cerebral amyloid angiopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Oxidized neprilysin in aging and Alzheimer's disease brains

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Reduced neprilysin in high plaque areas of Alzheimer brain: a possible relationship to deficient degradation of beta-amyloid peptide.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Relationship between beta amyloid peptide generating molecules and neprilysin in Alzheimer disease and normal brain

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Characterization of endopeptidase 3.4.24.11 ("enkephalinase") activity in human plasma and cerebrospinal fluid.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Cerebrospinal fluid neprilysin is reduced in prodromal Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

A novel potent vasoconstrictor peptide produced by vascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Alzheimer's disease beta-amyloid peptide is increased in mice deficient in endothelin-converting enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Regulation of steady-state beta-amyloid levels in the brain by neprilysin and endothelin-converting enzyme but not angiotensin-converting enzyme.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Degradation of the Alzheimer's amyloid beta peptide by endothelin-converting enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Molecular mechanisms of fibrinolysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

In vitro stimulation of tissue-type plasminogen activator by Alzheimer amyloid β-peptide analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Brain plasmin enhances APP alpha-cleavage and Abeta degradation and is reduced in Alzheimer's disease brains

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Matrix metalloproteinases and diseases of the CNS.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

A metalloproteinase inhibitor domain in Alzheimer amyloid protein precursor.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Proteolysis of A beta peptide from Alzheimer disease brain by gelatinase A.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Degradation of the Alzheimer disease amyloid beta-peptide by metal-dependent up-regulation of metalloprotease activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Characterization of Neutral Proteinases from Alzheimer-Affected and Control Brain Specimens: Identification of Calcium-Dependent Metalloproteinases from the Hippocampus

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Matrix metalloproteinase-9 degrades amyloid-beta fibrils in vitro and compact plaques in situ

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Signaling by the angiotensin-converting enzyme.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide (A beta ); retards A beta aggregation, deposition, fibril formation; and inhibits cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Amyloid beta-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Angiotensin Converting Enzyme in Alzheimer's Disease: Increased Activity in Caudate Nucleus and Cortical Areas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Angiotensin converting enzyme density is increased in temporal cortex from patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Cortical alterations of angiotensin converting enzyme, angiotensin II and AT1 receptor in Alzheimer's dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

ACE activity in CSF of patients with mild cognitive impairment and Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Emerging roles for cysteine proteases in human biology

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Enzymatically active lysosomal proteases are associated with amyloid deposits in Alzheimer brain

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Antiamyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Identification of Cathepsin B as a Mediator of Neuronal Death Induced by Aβ-activated Microglial Cells Using a Functional Genomics Approach

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Cerebrospinal fluid protein biomarkers for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Biomarkers of Alzheimer disease in plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Safety and acceptability of the research lumbar puncture.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Cerebrospinal fluid levels of amyloid precursor protein and amyloid beta-peptide in Alzheimer's disease and major depression - inverse correlation with dementia severity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Quantitative changes in the amyloid βA4 precursor protein in Alzheimer cerebrospinal fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Decreased levels of soluble amyloid beta-protein precursor in cerebrospinal fluid of live Alzheimer disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Decreased α-secretase-cleaved amyloid precursor protein as a diagnostic marker for Alzheimer's diseas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Measurement of alpha- and beta-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Biochemical evidence for the long-tail form (A beta 1-42/43) of amyloid beta protein as a seed molecule in cerebral deposits of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Tau and Abeta42 protein in CSF of patients with frontotemporal degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

APOE epsilon4 allele is associated with reduced cerebrospinal fluid levels of Abeta42.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Age-dependent change in the levels of Abeta40 and Abeta42 in cerebrospinal fluid from control subjects, and a decrease in the ratio of Abeta42 to Abeta40 level in cerebrospinal fluid from Alzheimer's disease patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Combination assay of CSF tau, A beta 1-40 and A beta 1-42(43) as a biochemical marker of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

The amyloid-beta (Abeta) peptide pattern in cerebrospinal fluid in Alzheimer's disease: evidence of a novel carboxyterminally elongated Abeta peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Amino-truncated beta-amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Determination of beta-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

An Alzheimer's disease-specific beta-amyloid fragment signature in cerebrospinal fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

High levels of circulating Abeta42 are sequestered by plasma proteins in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

PET of brain amyloid and tau in mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Cytosolic beta-amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Tissue inhibitors of matrix metalloproteinases are elevated in cerebrospinal fluid of neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Measurement of gelatinase B (MMP-9) in the cerebrospinal fluid of patients with vascular dementia and Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

CSF BACE1 activity is increased in CJD and Alzheimer disease versus [corrected] other dementias.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Detection of a soluble form of BACE-1 in human cerebrospinal fluid by a sensitive activity assay.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients : an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

CSF phosphorylated tau protein and mild cognitive impairment: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

One-carbon metabolism and other biochemical correlates of cognitive impairment as visualized by principal component analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Primary degenerative mild cognitive impairment: study population, clinical, brain imaging and biochemical findings.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Cerebrospinal fluid amyloid beta(1-42) levels in the mild cognitive impairment stage of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Cerebrospinal fluid markers for prediction of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Transgenic mouse models of Alzheimer's disease: how useful have they been for therapeutic development?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Selective Reductions in Plasma A 1-42 in Healthy Elderly Subjects During Longitudinal Follow-Up: A Preliminary Report

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

Tau protein isoforms, phosphorylation and role in neurodegenerative disorders11These authors contributed equally to this work

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.1.1.59

21 January 2018

Identifiers

DOI

10.2217/17520363.1.1.59

1 reference

22 August 2017

1 reference